Cocrystal Pharma has begun dosing healthy volunteers in a Phase 1b human challenge trial of its oral antiviral CDI‑988, the first direct‑acting agent aimed at preventing and treating norovirus infections. The study, registered as NCT07198139, will enroll up to 40 adults aged 18‑49 at Emory University School of Medicine and expose them to the GII.2 (Snow Mountain Virus) strain.
The trial is designed to evaluate the infectivity of the challenge inoculum and to collect early safety and efficacy data. CDI‑988 targets a highly conserved region of the viral 3CL protease, a mechanism that could provide broad‑spectrum activity across all known norovirus strains.
"Commencement of this study is a significant milestone for Cocrystal and a critical step toward addressing a serious global unmet medical need, given the debilitating symptoms and high societal cost of norovirus outbreaks." – Sam Lee, President and co‑CEO. "CDI‑988 has particular potential in high‑risk environments such as hospitals, nursing homes, cruise ships, schools and military facilities. The human challenge model is designed to provide proof‑of‑concept for our compound in a tightly controlled setting." – Sam Lee. "This challenge study is the first clinical trial involving a direct‑acting antiviral specifically targeting norovirus infections. The efficacy and safety data from this study are expected to provide a strong rationale for further clinical advancement of CDI‑988, and validate our proprietary structure‑based drug discovery platform technology." – Dr. Sam Lee.
The initiation of the Phase 1b trial follows FDA clearance to proceed in September 2025 and an Institutional Review Board approval from Emory in December 2025, clearing the way for the study. The company’s structure‑based drug discovery platform, which underpins CDI‑988, will be validated by the safety and efficacy data generated.
Cocrystal’s financial position supports continued clinical development. The company maintains a strong current ratio of 5.78 and holds more cash than debt, giving it flexibility to fund ongoing trials. Analysts have noted the company’s solid balance sheet and have raised confidence in its prospects, with recent price targets ranging from $6 to $8.
The norovirus market represents a substantial unmet need, with an estimated 685 million cases worldwide each year and a $60 billion economic burden. No approved treatments or vaccines exist, positioning CDI‑988 as a potentially first‑in‑class oral antiviral that could fill a critical therapeutic gap.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.